Skip to main content
Home Research Page 4

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/09/Tune-TherapeuticsTune-Therapeutics.jpeg

Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B

Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/11/Injecting-Hope-New-DT-Magazine-Hero-53-5.jpg

Injecting Hope

Researchers say injectable gel-like substance has healing powers for bone injuries. OsteoCure is an inventor booth at Invented at Duke 2024.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/10/Triangle-Venture-Day-badge-IMG_7088.jpg

Early-stage startups meet potential investors, partners at Triangle Venture Day

A total of 20 Triangle startups – including 4 with Duke roots – pitched their ideas to an audience that included more than 50 investor and strategic partnership groups at the Raleigh Convention Center.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/10/Inquisite-featured-image-Large.jpeg

New AI Product from Duke Professors Tackles Information Discovery and Synthesis

Jon Reifschneider, Pramod Singh and team developed Inquisite from their work running the Artificial Intelligence for Product Innovation Master's Program at Duke University’s Pratt School of Engineering.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/10/entrepreneurs-1536x1051-1.jpg

The Hard-Earned Lessons of Academic Entrepreneurs

Pratt I/O Magazine – Faculty entrepreneurs from Duke Engineering share their experiences of what it takes to spin a startup out of a university.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/09/FY2024-Press-Release-featured-image-v2.png

Duke Inventions Bring $82.6M in Revenue and Launch 6 New Start-Ups

$82.6M in revenue. 94 patents issued. 302 new invention disclosures. In a down year for new disclosures, OTC focuses on investing in the future.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/09/adaptin-bio-cover.png

Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma

Adaptin Bio is a Duke start-up based around glioblastoma-related technologies developed in the lab of Dr. John Sampson (Neurosurgery, SOM).

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/08/mri-with-brain-tumor-magnetic-resonance-imaging-2023-11-27-05-35-17-utc-Large.jpeg

New therapy for glioma receives FDA approval, leveraging cancer research conducted at Johns Hopkins & Duke University

Drs. Darell Bigner and Hai Yan (Neurosurgery, SOM) and colleagues identified the genetic mutation targeted by this new drug. Dr. Katherine Peters (Neurosurgery, SOM) was lead investigator in the clinical trials.

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2024/08/vq-biomedical-logo.png

VQ Biomedical receives $750K contract from BARDA / ASPR / HHS

VQ Biomedical is a start-up resulting from the collaboration of Assistant Professor Tobias Straube (Pediatrics, SOM) and Research Scientist Stewart Farling (CEE, Pratt).

Read More